{
  "Question": "Ingrowth Biotech CES 2024 product highlight and specification",
  "Summary": "Ingrowth Biotech\n\nCES 2024\n\n- The Global Biotechnology Industry Outlook 2024 report highlights the anticipated performance of the biotech and biopharma sectors, covering advancements in gene editing technologies and the development of innovative therapies.\n\n- Key market players include prominent companies such as Thermo Fisher Scientific Inc., Danaher, Becton, Dickinson and Company, GE HealthCare, Agilent Technologies, Merck KGAA, Qiagen, Illumina, F. Hoffmann-La Roche Ltd, Pfizer Inc., Novartis, Merck & Co., Sanofi, Amgen, Gilead Sciences, Biogen, Bristol Myers Squibb, and GSK.\n\n- The cell and gene therapy market is expected to experience a remarkable >20% increase from 2023 to 2024, reaching approximately USD 11 billion, with a substantial influx of approvals and numerous clinical trials.\n\n- Other key trends for 2024 include the significant contributions of Artificial Intelligence (AI) in biotechnology, the transformative tool of gene editing, and the pivotal impact of leveraging big data in biotechnology."
}